Skip to content

Transanal local full-thickness resection for cCR/ncCR rectal cancer after neoadjuvant chemoradiotherapy: a cohort study

Transanal local full-thickness resection for cCR/ncCR rectal cancer after neoadjuvant chemoradiotherapy: a cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063832
Enrollment
Unknown
Registered
2022-09-18
Start date
2022-09-18
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

TaMIS group:TaMIS group

Sponsors

Department of General Surgery, First Medical Center, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged between 18 and 80 years old; 2. Colonoscopy before nCRT treatment: The distance between the lower edge of the tumor and the anal edge is<=12cm, and pathological biopsy shows rectal adenocarcinoma; Combined with chest and abdominal CT, rectal MRI, and other examinations, the initial evaluation was<=cT1N0M0, and/or the initial evaluation was<=cT1-3N0M0. After nCRT, the clinical staging was re evaluated as<=ycT1N0M0 (cCR/ncCR); 3. ECOG<2; 4. Obtain informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1. Rectal cancer is more than 12cm away from the anal margin, and there are perforation, bleeding, obstruction, etc. before neoadjuvant radiotherapy and chemotherapy; 2. Patients with a history of pelvic radiation therapy; 3. Pregnant women; 4. Patients with distant organ metastasis or peritoneal implantation at the time of diagnosis; 5. Patients with tumors in other parts of the colon, including the colon, at the time of diagnosis; 6. Other concurrent or metachronous malignant tumors diagnosed within 5 years after the diagnosis of rectal cancer. 7. Subjects who are deemed unsuitable for participation in this study due to other reasons by the researcher; 8. Patients who refuse to participate or do not accept random allocation; 9. Patients with incomplete clinical information; 10. Patients who cannot be followed up.

Design outcomes

Primary

MeasureTime frame
3-year Disease-free survival (DFS);3-year local recurrence (LR);

Secondary

MeasureTime frame
3-year Overall survival (OS);

Countries

China

Contacts

Public ContactChaojun Zhang

First Medical Center, Chinese PLA General Hospital

798666882@qq.com+86 10 66938426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026